Status: Recruiting
Clenbuterol to Target DUX4 in FSHD
The purpose of this study is to determine if Clenbuterol is a therapeutic option for FSHD by determining the safety and tolerability of the medication at three different dose levels.
Participants needed: 30
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Jeffrey StatlandUpdated: Feb 25, 2026Locations: 3
Eligibility criteria
Genetically confirmed diagnosis of FSHD type 1 or 2, or have a clinical diagnosi... [+6]
Pregnant or planning to become pregnant during the conduct of the study [+8]